• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics plc - American Depositary Shares (NQ:BCYC)

4.170 +0.200 (+5.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bicycle Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Bicycle Therapeutics Enhances Leadership Team with Key Appointments
April 03, 2023
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates
March 28, 2023
From Bicycle Therapeutics plc
Via Business Wire
News headline image
What 8 Analyst Ratings Have To Say About Bicycle Therapeutics ↗
March 01, 2023
 
Via Benzinga
News headline image
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
February 28, 2023
From Bicycle Therapeutics
Via Business Wire
Looking Into Bicycle Therapeutics's Return On Capital Employed ↗
November 23, 2022
 
Via Benzinga
News headline image
Recap: Bicycle Therapeutics Q3 Earnings ↗
November 03, 2022
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Expert Ratings for Bicycle Therapeutics ↗
August 22, 2022
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings: 
Via Benzinga
News headline image
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 28, 2023
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009
February 14, 2023
From Bicycle Therapeutics
Via Business Wire
News headline image
Bicycle Therapeutics to Participate in the SVB Securities Global Biopharma Conference
February 08, 2023
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
January 11, 2023
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
January 04, 2023
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting
November 10, 2022
From Bicycle Therapeutics
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗
January 05, 2023
 
Via Benzinga
News headline image
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
November 08, 2022
From Bicycle Therapeutics
Via Business Wire
News headline image
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
November 04, 2022
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 03, 2022
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program
October 10, 2022
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics
September 19, 2022
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary ↗
September 07, 2022
 
Via Benzinga
News headline image
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors
September 07, 2022
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2022 ↗
August 31, 2022
Upgrades 
Via Benzinga
News headline image
Looking Into Bicycle Therapeutics's Return On Capital Employed ↗
August 22, 2022
According to data from Benzinga Pro, during Q2, Bicycle Therapeutics's (NASDAQ:BCYC) reported sales totaled $4.38 million. Despite a 2.67% increase in earnings, the company posted a loss of $26.83... 
Via Benzinga
News headline image
Bicycle Therapeutics: Q2 Earnings Insights ↗
August 04, 2022
  Bicycle Therapeutics (NASDAQ:BCYC) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 04, 2022
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides
August 02, 2022
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022 ↗
July 28, 2022
  
Via Benzinga
News headline image
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry
July 12, 2022
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
July 12, 2022
From Bicycle Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap